AXA1125
AXA1125 is an experimental drug developed by Axcella Health that "increased β-oxidation and improved bioenergetics in preclinical models". It was studied as a treatment for non-alcoholic fatty liver disease and long COVID.
AXA1125 is a fixed composition comprising five amino acids and an amino acid derivative .